NASDAQ:APYX Apyx Medical (APYX) Stock Price, News & Analysis $3.93 -0.16 (-3.91%) As of 11:48 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Apyx Medical Stock (NASDAQ:APYX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Apyx Medical alerts:Sign Up Key Stats Today's Range$3.93▼$4.0950-Day Range$2.79▼$4.3652-Week Range$1.41▼$4.50Volume28,860 shsAverage Volume153,338 shsMarket Capitalization$164.56 millionP/E RatioN/ADividend YieldN/APrice Target$6.50Consensus RatingModerate Buy Company Overview Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology. Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions. Its surgical devices are designed to enhance hemostasis, dissection and ablation in minimally invasive and open procedures, while its Renuvion system has gained adoption in cosmetic surgery for skin contraction and soft-tissue coagulation. The company supports its products with a combination of clinical training programs, customer service and collaborative research initiatives aimed at demonstrating safety and efficacy in various treatment settings. Established in early 2021 through a strategic combination of assets acquired from Bovie Medical, Apyx Medical has pursued a growth strategy centered on innovation and targeted commercial expansion. The company operates its headquarters in Clearwater, Florida, and maintains manufacturing and distribution capabilities to support an expanding global footprint. Guided by a leadership team with experience in medical technology and regulatory affairs, Apyx Medical continues to invest in product development and clinical evidence to broaden its treatment applications and enhance patient outcomes.AI Generated. May Contain Errors. Read More Apyx Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreAPYX MarketRank™: Apyx Medical scored higher than 42% of companies evaluated by MarketBeat, and ranked 634th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingApyx Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialApyx Medical has a consensus price target of $6.50, representing about 64.9% upside from its current price of $3.94.Amount of Analyst CoverageApyx Medical has only been the subject of 3 research reports in the past 90 days.Read more about Apyx Medical's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Apyx Medical is -18.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apyx Medical is -18.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApyx Medical has a P/B Ratio of 12.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Apyx Medical's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.62% of the float of Apyx Medical has been sold short.Short Interest Ratio / Days to CoverApyx Medical has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Apyx Medical has recently increased by 12.95%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldApyx Medical does not currently pay a dividend.Dividend GrowthApyx Medical does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Apyx Medical this week, compared to 3 articles on an average week. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Apyx Medical insiders have not sold or bought any company stock.Percentage Held by Insiders15.20% of the stock of Apyx Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.33% of the stock of Apyx Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Apyx Medical's insider trading history. Receive APYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apyx Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APYX Stock News HeadlinesBody by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the Runway1 hour ago | prnewswire.comApyx Medical Corporation (NASDAQ:APYX) Receives Average Rating of "Moderate Buy" from AnalystsMay 25 at 4:14 AM | americanbankingnews.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 27 at 1:00 AM | Profits Run (Ad)New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®May 21, 2026 | globenewswire.comApyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with LiposuctionMay 14, 2026 | globenewswire.comApyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring SystemMay 11, 2026 | finanznachrichten.deApyx Medical Corporation (NASDAQ:APYX) Released Earnings Last Week And Analysts Lifted Their Price Target To US$6.50May 11, 2026 | finance.yahoo.comApyx Medical Shares Rise After FDA Expands Clearance for AYON Liposuction FeatureMay 11, 2026 | marketwatch.comSee More Headlines APYX Stock Analysis - Frequently Asked Questions How have APYX shares performed this year? Apyx Medical's stock was trading at $3.50 at the beginning of the year. Since then, APYX shares have increased by 12.6% and is now trading at $3.9420. How were Apyx Medical's earnings last quarter? Apyx Medical Corporation (NASDAQ:APYX) announced its quarterly earnings data on Thursday, May, 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.06. The firm earned $12.49 million during the quarter, compared to the consensus estimate of $10.53 million. Apyx Medical had a negative net margin of 16.40% and a negative trailing twelve-month return on equity of 88.47%. Read the conference call transcript. Who are Apyx Medical's major shareholders? Top institutional shareholders of Apyx Medical include Silverberg Bernstein Capital Management LLC (2.49%), Sei Investments Co. (1.43%), Taylor Frigon Capital Management LLC (0.99%) and Renaissance Technologies LLC (0.72%). View institutional ownership trends. How do I buy shares of Apyx Medical? Shares of APYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Apyx Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apyx Medical investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/07/2026Today5/27/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 APYX's financial health is in the Green zone, according to TradeSmith. APYX has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:APYX CIK719135 Webwww.apyxmedical.com Phone(727) 384-2323Fax800-323-1640Employees270Year Founded1982Price Target and Rating Average Price Target for Apyx Medical$6.50 High Price Target$8.00 Low Price Target$6.00 Potential Upside/Downside+64.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.21 million Net Margins-16.40% Pretax Margin-15.58% Return on Equity-88.47% Return on Assets-14.94% Debt Debt-to-Equity Ratio2.68 Current Ratio5.80 Quick Ratio4.79 Sales & Book Value Annual Sales$55.90 million Price / Sales2.95 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book12.72Miscellaneous Outstanding Shares41,874,000Free Float35,509,000Market Cap$165.07 million OptionableOptionable Beta1.35 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:APYX) was last updated on 5/27/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apyx Medical Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Apyx Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
